An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumors Clinical Trial

Official title:

A Multicenter, Open Phase I Clinical Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-1826 for Injection in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06094556
• Other study ID #: SHR-1826-I-101
• Status: Recruiting
• Phase: Phase 1
• Start date: December 25, 2023
• Est. completion date: July 31, 2027

Study information

• Verified date: February 2024
• Source: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
• Contact: Yijun Jia
• Phone: +0518-81220121
• Email: yijun.jia[@]hengrui.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open, multi-center, dose-escalation/dose-expansion/efficacy expansion phase I clinical study to evaluate the tolerability, safety, PK, and immunogenicity of SHR-1826 in patients with advanced malignant solid tumors, and to preliminatively observe its antitumor efficacy. The whole study was divided into three stages: dose increment, dose extension and therapeutic effect extension.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 240
• Est. completion date: July 31, 2027
• Est. primary completion date: June 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Able and willing to provide a written informed consent.

2. =18 years old ,Male or female.

3. ECOG score is 0 or 1.

4. Subjects with advanced or metastatic solid tumors that have been documented by histopathology and are not responding to or tolerated by standard treatment, or have no effective standard treatment options.

5. Have at least one measurable lesion according to RECIST v1.1 criteria.

6. Expected survival =3 months .

7. With good vital organ function.

8. Contraception.

Exclusion Criteria:

1. With untreated or active Central nervous system (CNS) tumor metastasis. Subjects with a history or current history of meningeal metastasis.

2. Previous or co-existing malignant tumors.

3. Spinal cord compression that was not treated radically by surgery and/or radiotherapy was excluded.

4. Patients with uncontrolled tumor-related pain.

5. Received systemic antitumor therapy 4 weeks before starting study treatment; Previously receiving small molecule targeted therapy, the interval of not less than 5 half-lives of the drug can be enrolled.

6. Previously received antibody-coupled drug therapy.

7. Have undergone major surgery other than diagnosis or biopsy within 28 days prior to initial dosing; Minor traumatic surgery within 7 days prior to first dosing.

8. First study subjects receiving >30Gy non-radical chest radiation within 28 days prior to administration, >30Gy chest radiation within 24 weeks prior to first administration, and =30Gy palliative radiation within 14 days prior to first administration;If previously received radioisotope therapy, the interval of not less than 5 half-lives of the isotope drug can be included.

9. Is participating in another clinical study or the time of first administration is less than 4 weeks from the end of the previous clinical study (last administration), or the 5 half-life of the investigational drug, whichever is the older.

10. The AE caused by previous anti-tumor therapy did not recover to CTCAE v5.0 grade evaluation =1.

11. Other severe lung diseases that may interfere with the detection or management of drug-related pulmonary toxicity within the first three months of administration that significantly affect respiratory function; Any autoimmune, connective tissue, or inflammatory disease with lung involvement; Prior left or right total lung resection.

12. Pleural effusion, ascites, or pericardial effusion requiring intervention occurred within 2 weeks prior to the first dose.

13. Have an active autoimmune disease, or other acquired (HIV infection), congenital immunodeficiency disease, or a history of organ transplantation.

14. Have poorly controlled or severe cardiovascular disease.

15. Known hereditary or acquired bleeding and thrombotic tendencies, and clinically significant bleeding symptoms and arterial/venous thrombosis events in the 3 months prior to the first dose.

16. Untreated active hepatitis.

17. Subjects who had a severe infection within 30 days prior to the first dose; Patients with active pulmonary tuberculosis infection within 1 year prior to enrollment were found by medical history or CT examination, or had a history of active pulmonary tuberculosis infection more than 1 year ago but had not received regular treatment.

18. Live attenuated vaccine should be administered within 30 days prior to the first dose.

19. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.

20. Known allergy to any component or excipient of the SHR-1826 product.

21. The presence of other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of participation in the study, or interfere with the study results, as well as conditions that the investigator deems inappropriate to participate in the study.

Related Conditions & MeSH terms

• Advanced Solid Tumors
• Neoplasms

Intervention

Drug:
• SHR-1826
dose is calculated based on the subjects' baseline weight.

Locations

Country	Name	City	State
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting toxicity	evaluate the safety in the doses escalation	21 Days
Primary	Maximum tolerated dose or Maximum-administered dose	evaluate the safety in the doses escalation	Approximately 1 year
Primary	Recommended Phase 2 dose (RP2D)	evaluate the safety and curative effect in the doses escalation	Approximately 2 years
Secondary	Maximum concentration (Cmax) of SHR-1826	To evaluate the pharmacokinetic characteristics of SHR-1826	Approximately 2 years
Secondary	Time to maximum concentration (Tmax) of SHR-1826	To evaluate the pharmacokinetic characteristics of SHR-1826	Approximately 2 years
Secondary	Areas under the concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of SHR-1826	To evaluate the pharmacokinetic characteristics of SHR-1826	Approximately 2 years
Secondary	Areas under the concentration-time curve from time zero extrapolated to infinity (AUCinf) of SHR-1826	To evaluate the pharmacokinetic characteristics of SHR-1826	Approximately 2 years
Secondary	Half-life (t1/2) of SHR-1826	To evaluate the pharmacokinetic characteristics of SHR-1826	Approximately 2 years
Secondary	Mean retention times (MRT) of SHR-1826	To evaluate the pharmacokinetic characteristics of SHR-1826	Approximately 2 years
Secondary	Clearance rate (CL) of SHR-1826	To evaluate the pharmacokinetic characteristics of SHR-1826	Approximately 2 years
Secondary	Volume of distribution at the steady state (Vss) of SHR-1826	To evaluate the pharmacokinetic characteristics of SHR-1826	Approximately 2 years
Secondary	Anti-drug antibody of SHR-1826	To evaluate the pharmacokinetic characteristics of SHR-1826	Approximately 2 years
Secondary	Objective response rate (ORR)	Preliminary evaluation of the effectiveness of SHR-1826	Approximately 2 years
Secondary	Duration of response (DoR)	Preliminary evaluation of the effectiveness of SHR-1826	Approximately 2 years
Secondary	Disease control rate (DCR)	Preliminary evaluation of the effectiveness of SHR-1826	Approximately 2 years
Secondary	Progression free survival (PFS)	Preliminary evaluation of the effectiveness of SHR-1826	Approximately 2 years
Secondary	Overall survival (OS)	Preliminary evaluation of the effectiveness of SHR-1826	Approximately 2 years